Merck & Co., Inc. (NYSE:MRK) Position Boosted by Voloridge Investment Management LLC

Voloridge Investment Management LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 102.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,013 shares of the company’s stock after acquiring an additional 42,103 shares during the quarter. Voloridge Investment Management LLC’s holdings in Merck & Co., Inc. were worth $6,961,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Voleon Capital Management LP bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $37,733,000. Beutel Goodman & Co Ltd. grew its stake in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. Beutel Goodman & Co Ltd. now owns 553,753 shares of the company’s stock valued at $35,456,000 after buying an additional 1,877 shares in the last quarter. Doyle Wealth Management grew its stake in shares of Merck & Co., Inc. by 1.5% in the 2nd quarter. Doyle Wealth Management now owns 138,143 shares of the company’s stock valued at $11,583,000 after buying an additional 2,000 shares in the last quarter. Advisors Capital Management LLC grew its stake in shares of Merck & Co., Inc. by 8.8% in the 2nd quarter. Advisors Capital Management LLC now owns 74,459 shares of the company’s stock valued at $6,243,000 after buying an additional 6,001 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Merck & Co., Inc. by 6,517.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock valued at $2,038,169,000 after buying an additional 23,940,007 shares in the last quarter. 74.97% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on MRK shares. Citigroup boosted their price target on Merck & Co., Inc. from $84.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, June 21st. They noted that the move was a valuation call. Mizuho reissued a “buy” rating and issued a $97.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, September 8th. Svb Leerink started coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price target for the company. ValuEngine cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Goldman Sachs Group started coverage on Merck & Co., Inc. in a research note on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 price target for the company. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $93.29.



Merck & Co., Inc. stock traded down $0.50 during trading hours on Wednesday, reaching $83.10. 6,831,508 shares of the company were exchanged, compared to its average volume of 8,064,552. The firm has a market cap of $218.04 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.73 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average of $84.96 and a 200 day moving average of $82.03. Merck & Co., Inc. has a 12 month low of $66.10 and a 12 month high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 earnings per share. As a group, research analysts forecast that Merck & Co., Inc. will post 4.92 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.65%. Merck & Co., Inc.’s payout ratio is currently 50.69%.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Return on Investment (ROI) Defined, Explained

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.